Drug Sponsors

Biogen to spin off hemophilia business

Tuesday, May 3, 2016

Biogen intends to spin off its hemophilia business as an independent, publicly traded company. The strategic goal of this transaction is to create two focused companies dedicated to driving current and future value in their respective therapeutic areas of expertise.

[Read More]

EMD Serono expands biopharmaceutical R&D facility in Massachusetts

Tuesday, May 3, 2016

EMD Serono, the biopharmaceutical business of Merck, Darmstadt, Germany, in North America, has announced a $12 million investment for the expansion of its R&D facility in Billerica, Massachusetts. The new building will span more than 30,000 square feet and accommodate approximately 120 new and current employees whose focus will be on accelerating innovation in R&D, with a focus on oncology, immuno-oncology and immunology.

[Read More]

AbbVie to acquire Stemcentrx for $5.8B

Friday, April 29, 2016

AbbVie has announced it will acquire Stemcentrx and its lead late-stage asset rovalpituzumab tesirine (Rova-T), currently in registrational trials for small cell lung cancer (SCLC). Rova-T is a novel biomarker-specific therapy that is derived from cancer stem cells and targets delta-like protein 3 (DLL3) that is expressed in more than 80% of SCLC patient tumors and is not present in healthy tissue. Registrational trials for third-line small cell lung cancer are expected to complete enrollment by the end of 2016.

[Read More]

Daiichi Sankyo to open new U.S. headquarters in New Jersey

Tuesday, April 26, 2016

Daiichi Sankyo, Inc., the U.S. subsidiary of Daiichi Sankyo Company, Ltd., will establish a new U.S. headquarters, co-locating its commercial and development divisions in Basking Ridge, New Jersey. The move is part of an ongoing effort to realize efficiencies and continue collaboration between the business segments, enabling innovation in its existing and emerging therapeutic areas such as cardiology, oncology, pain and other areas where there are unmet medical needs.

[Read More]

Allergan acquires Topokine Therapeutics for fat reduction development program

Monday, April 25, 2016

Allergan, a global pharmaceutical company, has acquired Topokine Therapeutics, a privately held, clinical-stage biotechnology company focused on developing topical medicines for fat reduction. Allergan acquired Topokine Therapeutics for an upfront payment of $85 million and success-based development and sales milestones for XAF5, a first-in-class topical agent in late-stage development for the treatment of steatoblepharon, also known as undereye bags.

[Read More]